Our vision: ISNS is recognized worldwide for its contributions to the detection of neonatal conditions and the prevention of their adverse outcomes through excellence in neonatal screening.
Our mission: To enhance the quality of testing and medical services through dissemination of information, guidelines and best practices that benefit all family members and their babies by helping to ensure protection of babies from life-quality threatening conditions.
Welcome to the website of the International Society for Neonatal Screening (ISNS).
This society is aiming to advance screening for neonatal and infant sicknesses and disorders, worldwide.
ISNS has around 350 members in more than 70 different countries. Most members have a professional (para)medical background but a few are involved in parents' or patients' organisations.
For more information about ISNS visit the ISNS-Info section.
ISNS welcomes new members who have demonstrated an active interest in neonatal screening.
Why should I join as a member?
As a member you are entitled to see the privileged pages containing specific news items, a monthly neonatal screening literature service and a discount to ISNS-related conferences. Under certain conditions you may apply for travel grants to such conferences. Having access to the on line membership directory you have easier access to other members sharing specific interests.
How do I become a member?
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Jeffrey Modell Foundation
NEW YORK, Nov. 14, 2013 /PRNewswire-USNewswire/ -- 212 world renowned experts in Primary Immunodeficiency from 78 countries signed a "Berlin Declaration" calling for global implementation of newborn screening for Severe Combined Immunodeficiency (SCID), at the recently convened Berlin Summit organized by the Jeffrey Modell Foundation.
The meeting brought together physicians from the Jeffrey Modell Centers Network (JMCN) addressing new discoveries, innovative research, best practices, new treatment protocols, and the exploration of regional challenges and successes in the field. A major topic of discussion was the addition of SCID to Newborn Screening programs worldwide.
The test for SCID utilizes the TREC Assay. It provides the earliest possible identification of this life threatening condition and allows for early intervention of bone marrow transplantation before infants suffer from severe infections, organ damage, and ultimately, death. While other methods are currently being developed, the TREC Assay has the specificity and the sensitivity to accurately identify affected newborns.
Vicki and Fred Modell, Co-Founders of the Jeffrey Modell Foundation started the Newborn Screening Program in 2008. In 2010, The U.S. Secretary of Health and Human Services, Kathleen Sebelius, recognized the Jeffrey Modell Foundation's efforts and recommended that all newborns be screened for SCID, characterizing this type of screening as "The National Standard for Newborn Screening Programs". It was later added to the National Newborn Screening Core Panel. A total of 16 states in the United States are participating in this population screening process, and more than 60 percent of all newborns in the United States are now being screened for SCID. The program has shown that at least 1:33,000 tested positive for SCID.
The JMCN physicians have recognized the implementation of Newborn Screening for SCID as a global issue and believe this test should be the global standard. There is a 95 to 100 percent success rate of survivorship for babies transplanted in the first three months of life. It is essential these tests are conducted at birth because shortly after three months, the survival rate sharply declines, more serious infections develop, and fatality is inevitable. The physicians characterized SCID screening as a "pediatric emergency". The Berlin Declaration is a call to action for government health officials to not only recognize the importance of this test, but also to immediately implement it into their Newborn Screening programs.
About Jeffrey Modell Centers Network
JMCN is a program that includes 556 physicians at 234 academic institutions in 196 cities and 78 countries spanning 6 continents. This network connects centers and physicians from around the world, fostering meaningful interactions, cooperation, and new partnerships. This program has generated a 70 percent increase in identified patients worldwide over the past 18 months and inspires a continued encouragement and support of physician education and public awareness relating to all Primary Immunodeficiency disorders.
Vicki and Fred Modell, Co-Founders
Jeffrey Modell Foundation
Image with caption: "Jeffrey Modell Foundation." Image available at: http://photos.prnewswire.com/prnh/20131114/MM16675-a
Image with caption: "Jeffrey Modell Centers Summit." Image available at: http://photos.prnewswire.com/prnh/20131114/MM16675-b
©2012 PR Newswire. All Rights Reserved.
The Journal of Inborn Errors of Metabolism and Screening (JIEMS) is an online peer-reviewed open access journal devoted to publishing clinical and experimental research in inherited metabolic disorders and screening, for health professionals and scientists. Original research articles published in JIEMS range from basic findings that have implications for disease pathogenesis and therapy, passing through diagnosis and screening of metabolic diseases and genetic conditions, and therapy development and outcomes as well. Original articles, reviews on specific topics, brief communications and case reports are welcome.
JIEMS aims to become a key resource for geneticists, genetic counselors, biochemists, molecular biologists, reproductive medicine researchers, obstetricians/gynecologists, neonatologists, pediatricians, pathologists and other health professionals interested in inborn errors of metabolism and screening.